Scarica l'app Stockscreener
5.59
35.35%
1.46
Dopo l'orario di chiusura:
5.63
0.04
+0.72%
Precedente Chiudi:
$4.13
Aprire:
$5.37
Volume 24 ore:
10.52M
Relative Volume:
9.10
Capitalizzazione di mercato:
$362.34M
Reddito:
$202.09M
Utile/perdita netta:
$-61.69M
Rapporto P/E:
-5.1759
EPS:
-1.08
Flusso di cassa netto:
$-35.64M
1 W Prestazione:
+24.22%
1M Prestazione:
+21.79%
6M Prestazione:
-25.57%
1 anno Prestazione:
-61.05%
Intervallo 1D:
$5.065
$6.13
Intervallo di 1 settimana:
$4.10
$6.13
Portata 52W:
$4.0913
$14.60
Evolus Inc Stock (EOLS) Company Profile
Nome
Evolus Inc
Settore
Telefono
(949) 284-4555
Indirizzo
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
5.59 | 267.71M | 202.09M | -61.69M | -35.64M | -1.08 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.96 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.47 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-06 | Downgrade | Needham | Buy → Hold |
| 2025-04-17 | Iniziato | BTIG Research | Buy |
| 2024-01-29 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-06-23 | Iniziato | Needham | Buy |
| 2022-05-12 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-01-20 | Aggiornamento | Truist | Hold → Buy |
| 2021-05-06 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-04-08 | Reiterato | H.C. Wainwright | Buy |
| 2021-02-24 | Downgrade | Truist | Buy → Hold |
| 2020-07-07 | Downgrade | Mizuho | Buy → Neutral |
| 2020-02-06 | Ripresa | Mizuho | Buy |
| 2019-11-26 | Iniziato | SVB Leerink | Outperform |
| 2019-09-05 | Ripresa | Mizuho | Buy |
| 2019-06-28 | Iniziato | Wells Fargo | Market Perform |
| 2019-06-11 | Iniziato | Barclays | Underweight |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2019-02-14 | Iniziato | H.C. Wainwright | Buy |
| 2019-01-29 | Iniziato | Stifel | Buy |
Mostra tutto
Evolus Inc Borsa (EOLS) Ultime notizie
Evolus Q4 2025 slides: revenue growth continues despite forecast miss By Investing.com - Investing.com Australia
EOLS SEC FilingsEvolus 10-K, 10-Q, 8-K Forms - Stock Titan
Evolus posts record rally after Q4 beat (EOLS:NASDAQ) - Seeking Alpha
Evolus (NASDAQ:EOLS) Issues Quarterly Earnings Results - MarketBeat
Evolus' (EOLS) Buy Rating Reaffirmed at BTIG Research - MarketBeat
Evolus, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
BTIG Reiterates Buy Rating for Evolus (EOLS) with $13 Target | E - GuruFocus
US Stock Movement | Evolus rises over 16% pre-market as Q4 revenue growth achieves breakeven, positive guidance for this quarter - Bitget
Evolus (EOLS) Projects Growth with Strategic Initiatives and New Product Launches - GuruFocus
Evolus earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
Evolus Inc (EOLS) Q4 2025 Earnings Call Highlights: Strong Reven - GuruFocus
Aug Sectors: What analysts say about Evolus Inc stockTrade Risk Assessment & AI Enhanced Trading Alerts - baoquankhu1.vn
Earnings call transcript: Evolus misses Q4 2025 revenue forecast, stock dips - Investing.com South Africa
Evolus Q4 Earnings Call Highlights - MarketBeat
Evolus Shares Up 17% on Q4, Full Year Earnings - Orange County Business Journal
Evolus, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:EOLS) 2026-03-03 - Seeking Alpha
Evolus (EOLS) Q4 2025 Earnings Call Transcript - AOL.com
Evolus, Inc. (EOLS) Matches Q4 Earnings Estimates - Yahoo Finance
Evolus (NASDAQ: EOLS) outlines 2025 losses, Jeuveau and Evolysse growth plans - Stock Titan
EOLS Projects Strong Financial Growth Through 2028 - GuruFocus
Evolus : Investor Presentation - marketscreener.com
Evolus Incenters loan and security agreement with Eclipse Business Capital on March 3, 2026SEC filing - marketscreener.com
EOLS Reports Strong Q4 Revenue Surpassing Expectations - GuruFocus
Evolus Posts Q4 Breakeven Results, Revenue Rises; Shares Gain After Hours - marketscreener.com
Evolus 2025 10-K: $297.2M Revenue, $(0.80) EPS - TradingView
Evolus Secures New Credit Facility and Reports Profitability - TipRanks
Evolus Q4 Earnings Summary & Key Takeaways - Benzinga
Evolus Inc. (EOLS) Stock Rises on Q4 2025 Earnings - Quiver Quantitative
Evolus (NASDAQ: EOLS) wins $30M credit line and 12% 2025 sales rise - Stock Titan
Evolus, Inc. Provides Earnings Guidance for 2026 - marketscreener.com
EOLS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Evolus recently officially disclosed its financial results for the fourth quarter and full year of 2025. - Bitget
Evolus Shares Earn 'Moderate Buy' Rating from Analysts - National Today
What to Expect from Evolus's Earnings - Benzinga
Evolus, Inc. (NASDAQ:EOLS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Evolus, Inc. (EOLS) Stock Analysis: A 237% Potential Upside In The Healthcare Sector - DirectorsTalk Interviews
Evolus to join Leerink Partners Healthcare Conference for fireside chat and strategy talks - Traders Union
Evolus to Participate in The Leerink Partners Global Healthcare Conference - ChartMill
Evolus, Inc. (EOLS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Finviz
Evolus (EOLS) Expected to Announce Earnings on Tuesday - MarketBeat
Aug Highlights: How volatile is CTEV stockTrend Reversal & High Accuracy Investment Entry Signals - baoquankhu1.vn
Evolus, Inc. (EOLS) Stock Analysis: A Potential 243% Upside Ignites Investor Interest - DirectorsTalk Interviews
Evolus (EOLS) awards RSUs and stock options to officer Rui Avelar - Stock Titan
Evolus (NASDAQ: EOLS) grants RSUs, PSUs and options to executive David Moatazedi - Stock Titan
How sustainable is Evolus Inc. stock dividend payoutWeekly Stock Recap & Intraday High Probability Setup Alerts - mfd.ru
Director at Evolus (EOLS) receives 45,559 restricted stock units in equity grant - Stock Titan
Medtech Stocks Surge in After-Hours Trading: RxSight, Penumbra, and Evolus Take the Lead - Intellectia AI
Caligan exits Evolus (EOLS), amended filing shows 0% ownership - Stock Titan
Major holder Timothy P. Lynch reports 9.9% stake in Evolus (EOLS) - Stock Titan
Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026 - BioSpace
BTIG Initiates Coverage of Evolus (EOLS) with Buy Recommendation - MSN
Evolus Inc Azioni (EOLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.21%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):